Trial Profile
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms APeX-J
- Sponsors BioCryst Pharmaceuticals
- 18 Sep 2023 According to a BioCryst Pharmaceuticals media release, the Institut national dexcellence en sante et services sociaux (INESSS) has issued a positive recommendation for PrORLADEYO (berotralstat) to be reimbursed for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age and older in Quebec.
- 22 May 2023 According to a BioCryst Pharmaceuticals media release, the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.